Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Y0000271

Oxaliplatin

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Sign Into View Organizational & Contract Pricing

Select a Size

250 MG
$225.00

$225.00

Availability

Available to ship onJanuary 08, 2025Details

Request a Bulk Order
All Photos(1)

Select a Size

Change View
250 MG
$225.00

About This Item

Empirical Formula (Hill Notation):
C8H14N2O4Pt
CAS Number:
61825-94-3
Molecular Weight:
397.29
MDL number:
MFCD00866327
UNSPSC Code:
41116107
PubChem Substance ID:
329830895
NACRES:
NA.24

$225.00

Availability

Available to ship onJanuary 08, 2025Details

Request a Bulk Order

grade

pharmaceutical primary standard

API family

oxaliplatin

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Oxaliplatin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Product No.
Description
Pricing

Y0000275

Dichlorodiaminocyclohexaneplatinum, European Pharmacopoeia (EP) Reference Standard

Y0000273

Oxaliplatin impurity C, European Pharmacopoeia (EP) Reference Standard

Y0000274

Oxaliplatin impurity D, European Pharmacopoeia (EP) Reference Standard

Y0000272

Oxaliplatin impurity B, European Pharmacopoeia (EP) Reference Standard

1481204

Oxaliplatin, United States Pharmacopeia (USP) Reference Standard

1481226

Oxaliplatin Related Compound B, United States Pharmacopeia (USP) Reference Standard

1481215

Oxaliplatin Related Compound A, United States Pharmacopeia (USP) Reference Standard

1481237

Oxaliplatin Related Compound C, United States Pharmacopeia (USP) Reference Standard

1481248

Oxaliplatin Related Compound D, United States Pharmacopeia (USP) Reference Standard

1481306

Oxaliplatin System Suitability, United States Pharmacopeia (USP) Reference Standard

1481260

Oxaliplatin Related Compound F, United States Pharmacopeia (USP) Reference Standard

PHR2545

Oxaliplatin Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

pictograms

Health hazardCorrosion
GHS08,GHS05

signalword

Danger

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Noriho Iida et al.
Science (New York, N.Y.), 342(6161), 967-970 (2013-11-23)
The gut microbiota influences both local and systemic inflammation. Inflammation contributes to development, progression, and treatment of cancer, but it remains unclear whether commensal bacteria affect inflammation in the sterile tumor microenvironment. Here, we show that disruption of the microbiota
Bernard Nordlinger et al.
The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)
Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present
Catia Moutinho et al.
Journal of the National Cancer Institute, 106(1), djt322-djt322 (2013-11-26)
A major problem in cancer chemotherapy is the existence of primary resistance and/or the acquisition of secondary resistance. Many cellular defects contribute to chemoresistance, but epigenetic changes can also be a cause. A DNA methylation microarray was used to identify
Kristina Jansson et al.
Environmental and molecular mutagenesis, 54(5), 327-337 (2013-05-17)
The highly conserved DNA glycosylase MutY is implicated in repair of oxidative DNA damage, in particular in removing adenines misincorporated opposite 7,8-dihydro-8-oxoguanine (8-oxo-G). The MutY homologues (MutYH) physically associate with proteins implicated in replication, DNA repair, and checkpoint signaling, specifically
Roser Velasco et al.
Journal of neurology, neurosurgery, and psychiatry, 85(4), 392-398 (2013-07-03)
Peripheral neuropathy ranks among the most common dose-limiting and disabling side-effect of oxaliplatin (OXA)-based chemotherapy. The aim of this prospective, multicentre study was to define early clinical and neurophysiological markers that may help to identify patients at risk of developing
View All Related Papers

Questions

  1. Hello, Could you tell me the quantity of Y0000271 Oxaliplatin European Pharmacopoeia (EP) reference standard.  Bonjour, Pourriez-vous m'informer de la quantité de Y0000271 Oxaliplatine Standard de référence de la Pharmacopée européenne (EP). 

    1 answer

    1. This is a product of the European Pharmacopoeia. Each vial contains 250 mg of Oxaliplatin.

      Please see the link below to visit the European Pharmacopeia website for more information and to download the product leaflet: https://crs.edqm.eu/db/4DCGI/View=Y0000271

      Helpful?

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service